Pro/Con: Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 5, 2005, Pages 400-404

  Chang, David Z ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; VASCULOTROPIN ANTIBODY; VITAMIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; FOLINIC ACID; IFL PROTOCOL; PLATINUM COMPLEX;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; METASTASIS; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; RANDOMIZATION; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; MORTALITY; REVIEW; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 25844520775     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol. 1999;26(6):589-605.
2. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209-1214.
3. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with of without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947.
4. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136-147.
5. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results ofa phase III trial. J Clin Oncol. 2003;21(11):2059-2069.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
8. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-51.
9. Takebayashi Y, Yamada K Miyadera K, et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer. 1996;32A(7):1227-1232.
10. Budman DR,. Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16(5):1795-1802.
11. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18(6):1337-1345.
12. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292.
13. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-4106.
14. Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 2002;38(suppl 2):15-20.
15. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(11):2084-2091.
16. Jordan K, Kellner O, Mueller L. Capecitabine plus irinotecan or oxaliplatin in patients with advanced gastrointestinal tumors - results of a pilot study. Ann Oncol. 2002;13(suppl 5):79. Abstract 287.
17. Diaz-Rubio E, Evans TF, Tabemero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol. 2002;13(4):558-565.
18. Kakolyris S, Souglakos J, Kouroussis C, et al. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. Oncology. 2004;66(4):253-259.
19. Makatsoris T, Papadimitriou C, Karinà M. A phase II study of capecitabine and oxaliplatin as first line treatment for advanced colorectal carcinoma (CRC). A Hellenic Cooperative Oncology Group (HeCOG) study. Proc Am Soc Clin Oncol. 2003;22:360. Abstract 1447.
20. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol. 2003;14(9):1378-1382.
21. Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004;100(3):531-537.
22. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20(7):1759-1766.
23. Grothey A, Jordan K, Kellner O. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-fine therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2003;22:255. Abstract 1022.
24. Scheithauer W, Kornek GV, Raderer M, et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol. 2002;13(10):1583-1589.
25. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977-2985.
26. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003;21(7):1307-1312.
27. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
28. Carreca I, Comella P, Maiorino L. Oral capecitabine plus oxaliplatin (XELOX regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0108) phase II study. Proc Am Soc Clin Oncol. 2003;22:731. Abstract 2939.